Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 299128 | 3.91 |
09:34 ET | 61833 | 3.9599 |
09:36 ET | 85985 | 3.91 |
09:38 ET | 58067 | 3.965 |
09:39 ET | 53141 | 3.965 |
09:41 ET | 454681 | 4 |
09:43 ET | 62572 | 3.9605 |
09:45 ET | 70572 | 3.96 |
09:48 ET | 20567 | 3.97 |
09:50 ET | 99394 | 3.97 |
09:52 ET | 48205 | 4 |
09:54 ET | 48113 | 3.97 |
09:56 ET | 72564 | 3.98 |
09:57 ET | 94492 | 3.9723 |
09:59 ET | 49929 | 3.99 |
10:01 ET | 50008 | 3.98 |
10:03 ET | 49069 | 3.985 |
10:06 ET | 95080 | 3.965 |
10:08 ET | 60051 | 3.98 |
10:10 ET | 63208 | 3.9792 |
10:12 ET | 35990 | 3.995 |
10:14 ET | 254278 | 3.985 |
10:15 ET | 163731 | 4.005 |
10:17 ET | 139001 | 4.005 |
10:19 ET | 128517 | 4.005 |
10:21 ET | 158317 | 4.02 |
10:24 ET | 84693 | 4 |
10:26 ET | 301764 | 4.005 |
10:28 ET | 31091 | 3.995 |
10:30 ET | 312426 | 4 |
10:32 ET | 411196 | 3.995 |
10:33 ET | 393665 | 4 |
10:35 ET | 76536 | 3.965 |
10:37 ET | 48853 | 3.99 |
10:39 ET | 40643 | 3.975 |
10:42 ET | 108424 | 4.0099 |
10:44 ET | 383630 | 4 |
10:46 ET | 138292 | 4.0141 |
10:48 ET | 120632 | 4.03 |
10:50 ET | 333204 | 4.025 |
10:51 ET | 77359 | 4.02 |
10:53 ET | 78653 | 4.0188 |
10:55 ET | 48188 | 4.015 |
10:57 ET | 17958 | 4.01 |
11:00 ET | 7431 | 4.01 |
11:02 ET | 30106 | 4.015 |
11:04 ET | 13212 | 4.015 |
11:06 ET | 3183 | 4.01 |
11:08 ET | 49864 | 4.04 |
11:09 ET | 72567 | 4.0401 |
11:11 ET | 108915 | 4.035 |
11:13 ET | 6915 | 4.045 |
11:15 ET | 186583 | 4.06 |
11:18 ET | 47881 | 4.0768 |
11:20 ET | 181264 | 4.095 |
11:22 ET | 165305 | 4.105 |
11:24 ET | 148945 | 4.14 |
11:26 ET | 191449 | 4.16 |
11:27 ET | 338392 | 4.15 |
11:29 ET | 66780 | 4.1427 |
11:31 ET | 60821 | 4.15 |
11:33 ET | 179106 | 4.155 |
11:36 ET | 94590 | 4.135 |
11:38 ET | 80524 | 4.13 |
11:40 ET | 219537 | 4.155 |
11:42 ET | 140837 | 4.165 |
11:44 ET | 146682 | 4.175 |
11:45 ET | 122523 | 4.165 |
11:47 ET | 91732 | 4.155 |
11:49 ET | 13841 | 4.16 |
11:51 ET | 90543 | 4.19 |
11:54 ET | 30980 | 4.185 |
11:56 ET | 297342 | 4.19 |
11:58 ET | 110826 | 4.19 |
12:00 ET | 174650 | 4.215 |
12:02 ET | 129597 | 4.2199 |
12:03 ET | 90353 | 4.205 |
12:05 ET | 47071 | 4.215 |
12:07 ET | 176747 | 4.18 |
12:09 ET | 34520 | 4.195 |
12:12 ET | 468343 | 4.245 |
12:14 ET | 79596 | 4.235 |
12:16 ET | 175482 | 4.23 |
12:18 ET | 95591 | 4.225 |
12:20 ET | 53117 | 4.24 |
12:21 ET | 29092 | 4.235 |
12:23 ET | 71693 | 4.215 |
12:25 ET | 764817 | 4.185 |
12:27 ET | 87151 | 4.1889 |
12:30 ET | 92672 | 4.19 |
12:32 ET | 231301 | 4.1975 |
12:34 ET | 41056 | 4.185 |
12:36 ET | 22907 | 4.2 |
12:38 ET | 62847 | 4.2 |
12:39 ET | 66885 | 4.2 |
12:41 ET | 53632 | 4.2 |
12:43 ET | 394751 | 4.2 |
12:45 ET | 58753 | 4.185 |
12:48 ET | 36058 | 4.2 |
12:50 ET | 80136 | 4.2 |
12:52 ET | 72826 | 4.215 |
12:54 ET | 84633 | 4.18 |
12:56 ET | 40110 | 4.185 |
12:57 ET | 231976 | 4.23 |
12:59 ET | 354515 | 4.225 |
01:01 ET | 206393 | 4.2 |
01:03 ET | 71276 | 4.17 |
01:06 ET | 123186 | 4.205 |
01:08 ET | 49254 | 4.205 |
01:10 ET | 6200 | 4.205 |
01:12 ET | 96737 | 4.23 |
01:14 ET | 65798 | 4.215 |
01:15 ET | 45137 | 4.215 |
01:17 ET | 145388 | 4.2478 |
01:19 ET | 48193 | 4.245 |
01:21 ET | 138445 | 4.2479 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -13.1x | --- |
Vera Therapeutics Inc | 2.2B | -18.2x | --- |
Dyne Therapeutics Inc | 2.1B | -6.6x | --- |
Keros Therapeutics Inc | 2.1B | -11.4x | --- |
Avidity Biosciences Inc | 2.3B | -8.6x | --- |
Celldex Therapeutics Inc | 2.3B | -12.8x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $237.0K |
Shares Outstanding | 586.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.57 |
EPS | $-0.32 |
Book Value | $0.46 |
P/E Ratio | -13.1x |
Price/Sales (TTM) | 9,385.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -81,832.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.